Facebook-f Twitter Linkedin Youtube
SUBSCRIBE
Facebook-f Twitter Linkedin Youtube
SUBSCRIBE

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden: A Care Team Forum®

Program Overview

Cytomegalovirus (CMV) is one of the most common infectious complications in solid organ transplant (SOT) recipients. During this activity, the faculty will discuss best practices for prevention and treatment of CMV post-transplant and provide clinical pearls for managing difficult-to-treat CMV, including refractory or drug-resistant disease. You will learn first-hand from a patient with CMV about the burden and very personal aspects of this disease.

Credit Expired
PARTICIPATE

Target Audience

Transplant, infectious disease, internal medicine, nephrologists, primary care, pharmacy clinicians, advanced practice providers, and surgeons managing patients with CMV 

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Assess the burden, risk factors, and impact of cytomegalovirus (CMV) on post-solid organ transplant (SOT) outcomes
  • Utilize antiviral therapies for CMV prophylaxis and preemptive treatment in SOT recipients
  • Manage refractory or resistant CMV in SOT recipients, incorporating recent advances in antiviral therapy

Activity Faculty

Razonable_Raymund_2021

Raymund R. Razonable, MD, FIDSA, FAST

Professor, Medicine
Program Director, Infectious Diseases Fellowship Program
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, MN

62-22-1045 CMV Faculty Headshot-SILVEIRA_FERNANDA

Fernanda P. Silveira, MD, MS, FIDSA, FAST 

Professor, Medicine
Director, Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh Medical Center
Pittsburgh, PA

Featured RMEI CE Activities

VIEW All RMEI CE ACTIVIES

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources

Join Now!